AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37870969 — intervention group
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 291
Study 37870969 — intervention group
Group type: COMPARATOR
Intervention: Cabozantinib or Vandetanib (Control)
Number of subjects: 291
Study 37870974 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 802
Study 37870974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 802
Study 37870973 — intervention group
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 212
Study 37870973 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (platinum-based chemotherapy with or without pembrolizumab)
Number of subjects: 212
Study 37870976 — intervention group
Group type: EXPERIMENTAL
Intervention: Amivantamab-chemotherapy
Number of subjects: 308
Study 37870976 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 308
Study 37871102 — intervention group
Group type: EXPERIMENTAL
Intervention: ETCO2 detection using sidestream capnography
Number of subjects: 0
Study 37871102 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnography
Number of subjects: 0
Study 37871300 — intervention group
Group type: EXPERIMENTAL
Intervention: U2-VeN (venetoclax, umbralisib, and ublituximab)
Number of subjects: 51
Study 37871306 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab consolidation after auto-SCT
Number of subjects: 14
Study 37871309 — intervention group
Group type: EXPERIMENTAL
Intervention: Enasidenib (ENA) monotherapy
Number of subjects: 77
Study 37871309 — intervention group
Group type: EXPERIMENTAL
Intervention: Enasidenib (ENA) with azacitidine
Number of subjects: 77
Study 37871332 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine plus bupivacaine hydrochloride
Number of subjects: 104
Study 37871332 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine hydrochloride alone
Number of subjects: 104
Study 37871403 — intervention group
Group type: EXPERIMENTAL
Intervention: CNSI patients overall
Number of subjects: 451
Study 37871403 — intervention group
Group type: EXPERIMENTAL
Intervention: Encephalitis
Number of subjects: 451
Study 37871403 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningitis
Number of subjects: 451
Study 37871403 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain abscess
Number of subjects: 451
Study 37871452 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 92
Study 37871452 — intervention group
Group type: EXPERIMENTAL
Intervention: STAIR
Number of subjects: 92
Study 37871452 — intervention group
Group type: COMPARATOR
Intervention: SNT
Number of subjects: 92
Study 37871528 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 316
Study 37871528 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 316
Study 37871555 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (DT) with dolutegravir or darunavir/cobicistat plus lamivudine
Number of subjects: 40
Study 37871555 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (TT) with integrase inhibitors
Number of subjects: 40
Study 37871576 — intervention group
Group type: EXPERIMENTAL
Intervention: Giroctocogene fitelparvovec gene therapy (3 × 10^13 vg/kg)
Number of subjects: 11
Study 37871576 — intervention group
Group type: EXPERIMENTAL
Intervention: Giroctocogene fitelparvovec gene therapy
Number of subjects: 11
Study 37871603 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal listeriosis
Number of subjects: 53
Study 37871603 — intervention group
Group type: COMPARATOR
Intervention: Gestational age-matched control children without infection
Number of subjects: 53
Study 37871604 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg combined with trastuzumab plus fluoropyrimidine and platinum-based chemotherapy
Number of subjects: 698
Study 37871604 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with trastuzumab plus fluoropyrimidine and platinum-based chemotherapy
Number of subjects: 698
Study 37871608 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus bevacizumab (1200 mg atezolizumab plus 15 mg/kg bevacizumab every 3 weeks for 17 cycles)
Number of subjects: 668
Study 37871608 — intervention group
Group type: COMPARATOR
Intervention: Active surveillance
Number of subjects: 668
Study 37871684 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Disability Index (PDI)
Number of subjects: 120
Study 37871684 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Form 36-item mental component (SF-36 MC)
Number of subjects: 120
Study 37871684 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Form 36-item physical component (SF-36 PC)
Number of subjects: 120
Study 37871684 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined effect of all pain cognitions on SF-36 PC
Number of subjects: 120
Study 37871703 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) + Enfortumab vedotin (EV) administered on days 1 + 8 of a 21-day cycle until progression or unacceptable toxicity.
Number of subjects: 23
Study 37871703 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) + Enfortumab vedotin (EV)
Number of subjects: 23
Study 37871703 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) 8 mg/kg with Enfortumab vedotin (EV) 1.25 mg/kg with granulocyte colony-stimulating factor support; MTDs are SG 10 mg/kg with EV 1.25 mg/kg.
Number of subjects: 23
Study 37871747 — intervention group
Group type: EXPERIMENTAL
Intervention: Homestead food production intervention
Number of subjects: 2701
Study 37871751 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton therapy
Number of subjects: 0
Study 37871751 — intervention group
Group type: COMPARATOR
Intervention: Photon therapy
Number of subjects: 0
Study 37871841 — intervention group
Group type: EXPERIMENTAL
Intervention: Snare Tip Soft Coagulation (STSC)
Number of subjects: 384
Study 37871841 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon Plasma Coagulation (APC)
Number of subjects: 384
Study 37871841 — intervention group
Group type: COMPARATOR
Intervention: No Margin Treatment (Control)
Number of subjects: 384
Study 37871841 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 384
Study 37871959 — intervention group
Group type: EXPERIMENTAL
Intervention: KIM-1
Number of subjects: 244
Study 37871959 — intervention group
Group type: EXPERIMENTAL
Intervention: sTNFR1
Number of subjects: 244
Study 37871959 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF and arginine-to-citrulline ratio
Number of subjects: 244
Study 37871959 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline sTNFR1, uromodulin, and EGF concentrations
Number of subjects: 244
Study 37871997 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intensive and sustained vasodilatation
Number of subjects: 288
Study 37871997 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 288
Study 37872020 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab plus axitinib (240 mg intravenously once every 3 weeks + 5 mg orally twice daily)
Number of subjects: 421
Study 37872020 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (50 mg orally once daily for 4 weeks or 2 weeks)
Number of subjects: 421
Study 37872059 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% CsA-CE
Number of subjects: 0
Study 37872059 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% CsA-CE
Number of subjects: 0
Study 37872059 — intervention group
Group type: COMPARATOR
Intervention: 0.05% CsA-CE and 0.1% CsA-CE
Number of subjects: 0
Study 37872059 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 37872092 — intervention group
Group type: EXPERIMENTAL
Intervention: Different diagnostic criteria for assessing mild micro-hepatic encephalopathy
Number of subjects: 0
Study 37872092 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37872225 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-T cells targeting CLDN6
Number of subjects: 22
Study 37872225 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-T cells targeting CLDN6 plus CARVac
Number of subjects: 22
Study 37872225 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose level (DL) treatment
Number of subjects: 22
Study 37872479 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional Care Stroke Intervention (TCSI)
Number of subjects: 90
Study 37872479 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 90
Study 37872492 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine
Number of subjects: 0
Study 37872492 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37872497 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg)
Number of subjects: 120
Study 37872497 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 120
Study 37872499 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 8
Study 37872499 — intervention group
Group type: EXPERIMENTAL
Intervention: Enema +
Number of subjects: 8
Study 37872499 — intervention group
Group type: EXPERIMENTAL
Intervention: Enema ÷
Number of subjects: 8
Study 37872504 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Level Interventions for Pre-eclampsia (CLIP) Trial
Number of subjects: 76
Study 37872582 — intervention group
Group type: EXPERIMENTAL
Intervention: MI plus omega 3
Number of subjects: 483
Study 37872582 — intervention group
Group type: COMPARATOR
Intervention: Combined intervention (MI plus omega 3)
Number of subjects: 483
Study 37872582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 483
Study 37872617 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program (SEP)
Number of subjects: 166
Study 37872617 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based structured exercise program (HSEP)
Number of subjects: 166
Study 37872617 — intervention group
Group type: COMPARATOR
Intervention: Walk advice (WA)
Number of subjects: 166
Study 37872628 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level tragus stimulation (LLTS)
Number of subjects: 100
Study 37872628 — intervention group
Group type: COMPARATOR
Intervention: Sham LLTS
Number of subjects: 100
Study 37872639 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling on safe use of prescribed opioids
Number of subjects: 247
Study 37872639 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids prescribed at discharge
Number of subjects: 247
Study 37872639 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent survey on discussions about safe use of pain medications
Number of subjects: 247
Study 37872639 — intervention group
Group type: EXPERIMENTAL
Intervention: AOD screening results
Number of subjects: 247
Study 37872639 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling documentation by sex, age, race, ethnicity, and AOD use
Number of subjects: 247
Study 37872639 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent survey results on counseling
Number of subjects: 247
Study 37872654 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical Composite End Point (HCE)
Number of subjects: 7
Study 37872654 — intervention group
Group type: EXPERIMENTAL
Intervention: Win Odds (WO) for treatment effects on HCE
Number of subjects: 7
Study 37872654 — intervention group
Group type: COMPARATOR
Intervention: Hazard Ratio (HR) of the primary kidney outcome
Number of subjects: 7
Study 37872725 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal cardiopulmonary resuscitation (ECPR)
Number of subjects: 0
Study 37872725 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiopulmonary resuscitation (CCPR)
Number of subjects: 0
Study 37872725 — intervention group
Group type: EXPERIMENTAL
Intervention: ECPR
Number of subjects: 0
Study 37872763 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic period (May to December 2021)
Number of subjects: 22650
Study 37872763 — intervention group
Group type: COMPARATOR
Intervention: Pre-COVID-19 period (January 2018 to April 2020)
Number of subjects: 22650
Study 37872763 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare system capacity during COVID-19
Number of subjects: 22650
Study 37873555 — intervention group
Group type: EXPERIMENTAL
Intervention: Enpatoran 50 mg
Number of subjects: 149
Study 37873555 — intervention group
Group type: EXPERIMENTAL
Intervention: Enpatoran 100 mg
Number of subjects: 149
Study 37873555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 37873786 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncolytic reovirus treatment administered for 5 days every 28 days.
Number of subjects: 0
Study 37873863 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI7247 (pyrrolobenzodiazepine antibody-drug conjugate)
Number of subjects: 0
Study 37874020 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic-valve replacement (TAVR)
Number of subjects: 1000
Study 37874020 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic-valve replacement
Number of subjects: 1000
Study 37874103 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 grams of DHA per day
Number of subjects: 368
Study 37874103 — intervention group
Group type: COMPARATOR
Intervention: Identically appearing placebo
Number of subjects: 368
Study 37874110 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain Health Support Program intervention for 45-weeks
Number of subjects: 350
Study 37874111 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone tablet
Number of subjects: 1330
Study 37874403 — intervention group
Group type: EXPERIMENTAL
Intervention: Night shift load
Number of subjects: 730
Study 37874574 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongxinluo
Number of subjects: 3777
Study 37874574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3777
Study 37874612 — intervention group
Group type: EXPERIMENTAL
Intervention: Managing Minds at Work (MMW) digital training intervention
Number of subjects: 224
Study 37874612 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 224
Study 37874619 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered on the tablet app using a chatbot interface
Number of subjects: 47
Study 37874619 — intervention group
Group type: EXPERIMENTAL
Intervention: Administered by an in-person clinician
Number of subjects: 47
Study 37874619 — intervention group
Group type: EXPERIMENTAL
Intervention: Administered by a telehealth clinician
Number of subjects: 47
Study 37874630 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week high-intensity strength training program
Number of subjects: 27
Study 37874637 — intervention group
Group type: EXPERIMENTAL
Intervention: NOLA GEM (just-in-time adaptive mHealth intervention)
Number of subjects: 60
Study 37874637 — intervention group
Group type: COMPARATOR
Intervention: GEMA-alone (control)
Number of subjects: 60
Study 37874657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory patients (AMBU)
Number of subjects: 79
Study 37874657 — intervention group
Group type: COMPARATOR
Intervention: Hospitalized patients (HOSP)
Number of subjects: 79
Study 37874655 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution antropyloroduodenal manometry (HR-ADM) during postprandial period
Number of subjects: 60
Study 37874831 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 870
Study 37874831 — intervention group
Group type: COMPARATOR
Intervention: Fecal immunochemical testing (FIT)
Number of subjects: 870
Study 37874908 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR + LAAO
Number of subjects: 349
Study 37874908 — intervention group
Group type: COMPARATOR
Intervention: TAVR + medical therapy
Number of subjects: 349
Study 37874913 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemotherapy (mostly R-CHOP 75% and reduced dose R-CHOP 13%)
Number of subjects: 645
Study 37874913 — intervention group
Group type: EXPERIMENTAL
Intervention: REALYSA cohort
Number of subjects: 645
Study 37874963 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch (TT)
Number of subjects: 108
Study 37874963 — intervention group
Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 108
Study 37874963 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108
Study 37875064 — intervention group
Group type: EXPERIMENTAL
Intervention: Amulet device
Number of subjects: 0
Study 37875064 — intervention group
Group type: COMPARATOR
Intervention: Watchman device
Number of subjects: 0
Study 37875144 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant cemiplimab 350 mg intravenously every 3 weeks followed by curative-intent surgery
Number of subjects: 79
Study 37875144 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant cemiplimab followed by surgery
Number of subjects: 79
Study 37875144 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant cemiplimab
Number of subjects: 79
Study 37875143 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 1579
Study 37875143 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 1579
Study 37875178 — intervention group
Group type: EXPERIMENTAL
Intervention: Group prenatal care
Number of subjects: 1256
Study 37875178 — intervention group
Group type: COMPARATOR
Intervention: Individual prenatal care
Number of subjects: 1256
Study 37875310 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantothenate kinase activation
Number of subjects: 0
Study 37875310 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37875323 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimberelimab (240 mg every 2 weeks for 2 years)
Number of subjects: 105
Study 37875337 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi training
Number of subjects: 330
Study 37875429 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 52
Study 37875429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 37875494 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab and ipilimumab
Number of subjects: 0
Study 37875524 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline FDG-PET/CT radiomics
Number of subjects: 0
Study 37875559 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic compound AB001 at single dose
Number of subjects: 81
Study 37875559 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic compound AB001 at double dose
Number of subjects: 81
Study 37875559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 37875578 — intervention group
Group type: EXPERIMENTAL
Intervention: zuranolone 50 mg co-initiated with standard-of-care antidepressant therapy (ADT)
Number of subjects: 425
Study 37875578 — intervention group
Group type: COMPARATOR
Intervention: placebo co-initiated with standard-of-care antidepressant therapy (ADT)
Number of subjects: 425
Study 37875637 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewable beetroot-based supplement (BR-CT)
Number of subjects: 44
Study 37875637 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 44
Study 37875714 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab reference product (adalimumab RP; Humira)
Number of subjects: 0
Study 37875714 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 695501
Number of subjects: 0
Study 37875771 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib in combination with cetuximab
Number of subjects: 0
Study 37875771 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib-cetuximab combination
Number of subjects: 0
Study 37875771 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab monotherapy
Number of subjects: 0
Study 37875792 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate dose enoxaparin (60 mg for 45-60 kg, 80 mg for 61-100 kg, 100 mg for >100 kg) once daily for 14 days, with dose adjustment according to anti-factor Xa activity.
Number of subjects: 301
Study 37875792 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate dose enoxaparin (IC)
Number of subjects: 301
Study 37875792 — intervention group
Group type: COMPARATOR
Intervention: Observational cohort (OC) receiving enoxaparin 40 mg/day
Number of subjects: 301
Study 37875813 — intervention group
Group type: EXPERIMENTAL
Intervention: SAP group (50 patients)
Number of subjects: 164
Study 37875813 — intervention group
Group type: EXPERIMENTAL
Intervention: VAP group (10 patients)
Number of subjects: 164
Study 37875813 — intervention group
Group type: COMPARATOR
Intervention: Nonpneumonia group (104 patients)
Number of subjects: 164
Study 37875813 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower abundance of Streptococcus in SAP patients
Number of subjects: 164
Study 37875813 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in specific taxa in the phylum Actinobacteriota
Number of subjects: 164
Study 37875813 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral microbiota model for SAP patients
Number of subjects: 164
Study 37875818 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 1 (clinicopathology and ultrasound)
Number of subjects: 124
Study 37875818 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 2 (clinicopathology, ultrasound, and PET)
Number of subjects: 124
Study 37875818 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 3 (clinicopathology, ultrasound, PET, and radiomics)
Number of subjects: 124
Study 37875818 — intervention group
Group type: COMPARATOR
Intervention: Positive axillary LNM group
Number of subjects: 124
Study 37875818 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics score for predicting LNM (RS_LNM)
Number of subjects: 124
Study 37875835 — intervention group
Group type: EXPERIMENTAL
Intervention: Software-based measurement-based care (MBC)
Number of subjects: 33
Study 37875851 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural intervention targeting school and parent levels
Number of subjects: 3100
Study 37875851 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural intervention combined with group-based Motivational Interviewing (group MI)
Number of subjects: 3100
Study 37875851 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 3100
Study 37875856 — intervention group
Group type: EXPERIMENTAL
Intervention: Tango-therapy
Number of subjects: 31